
EULAR 2018

Read the full Report (pdf)
European League Against Rheumatism 13-16 June 2018 Amsterdam, the Netherlands
Featured articles

CONTENTS
Online First
Rheumatoid Arthritis
Early, intensive rheumatoid arthritis treatment seems to normalise mortality rates
Switching to biosimilar bDMARDs is safe and efficacious

No significant differences when tapering TNF blockers versus csDMARDs
Biologic drug levels and infection risk, and clinical effectiveness of sarilumab

Confirmation of long-term safety profile adalimumab across indications
Ankylosing Spondylitis
Clinical effect of vedolizumab on articular manifestations spondyloarthritis associated with IBD
